Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease

BACKGROUND: Erdheim‐Chester disease (ECD) is a rare non‐Langerhans cell histiocytosis. The BRAF inhibitor vemurafenib is approved by the U.S. Food and Drug Administration (FDA) for patients with ECD harboring a BRAF V600E mutation. Successful treatment has also been reported with MEK‐targeted therap...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Saunders, Ila M., Goodman, Aaron M., Kurzrock, Razelle
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2019
Ämnen:
Brief Communications
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011668/
https://ncbi.nlm.nih.gov/pubmed/32043767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0606
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk